PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds Aesku.Diagnostics for Providing an Overall Analysis Platform for a Wide Range of Autoimmune Complications - Frost & Sullivan recognizes Aesku.Diagnostics with the 2008 European Frost & Sullivan Product Line Strategy Award for its consistent approach towards product development
Frost & Sullivan Lauds Aesku.Diagnostics for Providing an Overall Analysis Platform for a Wide Range of Autoimmune Complications

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/03/03 - Frost & Sullivan recognizes Aesku.Diagnostics with the 2008 European Frost & Sullivan Product Line Strategy Award for its consistent approach towards product development.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the autoimmune disease diagnostics markets, Frost & Sullivan recognizes Aesku.Diagnostics with the 2008 European Frost & Sullivan Product Line Strategy Award for its consistent approach towards product development. It has anticipated and catered to the needs in bio-marker identification, offered versatile immunoassay systems, extended research capabilities as well as delivered unprecedented sensitivity and exceptional performance.

In just eight years of its existence, Aesku.Diagnostics has acquired several antigen and therapy patents and has become a recognised name in the autoimmune diagnostics market in more than 80 countries. It has earned a solid reputation in the market for launching over 140 different products, catering to autoimmune diagnostics and laying equal emphasis on all the major disease sectors under the autoimmune disease diagnostic space.

"Its products fall under two major brands namely, AESKULISA® {enzyme-linked immunosorbent assays (ELISA) kits} and AESKUSLIDES® (immunofluorescence slide panels)," says Frost & Sullivan Suraj Ramanathan. "The AESKU tests are developed based on human recombinant antigens or native antigens (conformational epitopes) depending on the optimal clinical correlation."

ELISA kits are more popular for autoimmune diagnosis; the company provides more than 100 CE marked kits incorporating human recombinant antigens synthesized in-house to assure maximum sensitivity and specificity. The kits can be used for diagnosing rheumatology, thrombosis, gastroenterology, vasculitis, thyroid, diabetes, hepatology and other rare autoimmune complications. While its 30-30-30 test format can be used with most commercially available automated test platforms, its special in-house plate coating and production facility offers a shelf life of up to 24 months with a production capacity of nearly 500 plates per hour.

The AESKUSLIDES® brand encompasses a broad portfolio of immunofluorescence slides. All these slides are vacuum-sealed for longer shelf life as well as stability, and use a highly hydrophobic Teflon mask to avoid sample cross contamination.

Such innovations point to a strong focus on research. Aesku.Diagnostics is looking to centralise its research and production to provide a universal protocol compatible with both automated and manual handling of assays. This development methodology, known as the 'ONE' Aesku concept, includes one working protocol, one pre-dilution ratio, one buffer system, one reagent system, one calibration range, one cut-off and one assay platform for all available Aesku tests.

"The 'ONE' clearly improves the lab throughput and reduces the diagnosis time," notes Suraj Ramanathan. "Furthermore, the company has always adhered to providing customers with uninterrupted services and implementing novel strategies such as 'second opinion lab service', which aid customers with queries regarding sample diagnosis on a complementary basis."

Aesku.Diagnostics has also noted the necessity of automation in the autoimmunity lab, considering a tender is incomplete if the manufacturer/distributor does not offer automation of the tests. To address this need, it has developed HELMED®, an automatic flexible processor capable of running and managing routine tests for autoimmunity and infectious serology within the laboratory.

The HELMED® project, together with the already implemented Aesku 'ONE; concept (the same reagent system and protocol being shared by the complete reagent panel), will give the company the tools and arguments to consolidate sales in mature markets," observes Ramanathan. "It will also increase market shares in the developing markets and have full control of the automation key, so important for the future of the business."

Each year, Frost & Sullivan presents this award to the company that has demonstrated the most insight into customer needs and product demands. The recipient company should have optimized its product line by leveraging products with the various price, performance, and feature points required by the market.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About Aesku.Diagnostics
Aesku.Diagnostics (aesku.com), based in Wendelsheim, Germany, is a research-focused supplier of innovative and efficient products and services for the early detection, diagnosis and prognosis of autoimmune diseases. In only nine years since its foundation Aesku has become a recognized name in the autoimmune diagnostics market for launching over 140 different products clearly improving the lab throughput together with uninterrupted services in more than 80 countries worldwide. With Aesku.Systems (Lab automation) and Aesku.Therapy (Autoimmune Therapies) the company diversifies its portfolio consistently to meet upcoming needs in the autoimmune diseases sector.

Contact:
Hugo Ribeiro, International Sales Manager
AESKU.DIAGNOSTICS
ribeiro@aesku.com
P: +49 (0) 6734.9627.0
F: +49 (0) 6734.9627.27

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds Aesku.Diagnostics for Providing an Overall Analysis Platform for a Wide Range of Autoimmune Complications

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Ciara Jamie Connolly 
+44 (0) 207.915.7868 ciara.connolly[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)